Detection of circulating cells expressing chromogranin A gene transcripts in patients with lung neuroendocrine carcinoma.
High grade lung neuroendocrine carcinomas, like small and large cell neuroendocrine carcinomas, pose therapeutic problems. Most initially respond to chemotherapeutic agents, but early relapses are frequent and are resistant to the presently available treatments. Our study reports for the first time the development and evaluation of a test for detecting the presence of circulating tumour cells by measuring chromogranin A gene transcripts with reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blotting. The test is specific and sensitive (detection of 10 cancer cells/ml blood), and only minimally invasive. Positivity is statistically correlated to high grade neuroendocrine carcinomas and to a poor prognosis with a 3-fold higher lethal risk. The test now needs to be assessed for its usefulness as a tool in the initial staging procedures and follow-up by comparison with the recent immunoradiometric assay (RIA) for detection of chromogranin A in the serum.
Bégueret
H
H
Service d'Anatomie Pathologique, Hôpital Haut-Lévêque, Avenue Magellan, 33604 Cedex, Pessac, France. hugues.begueret@chu-bordeaux.fr
Vergier
B
B
Bégueret
J
J
Vernejoux
J M
JM
Jougon
J
J
Trouette
R
R
Taytard
A
A
Velly
J F
JF
Merlio
J P
JP
de Mascarel
A
A
D017398:Alternative Splicing; D015139:Blotting, Southern; D018278:Carcinoma, Neuroendocrine / Q000235:genetics*; D053379:Chromogranin A; D002864:Chromogranins / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D009360:Neoplastic Cells, Circulating / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins